(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/027041 A1

(51) International Patent Classification:
A61K 9/06 (2006.01) *A61K 31/433* (2006.01)
A61K 9/107 (2006.01)

(21) International Application Number:
PCT/US2021/071019

(22) International Filing Date:
27 July 2021 (27.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/057,503 28 July 2020 (28.07.2020) US

(71) Applicant: **ARCUTIS BIOTHERAPEUTICS, INC.** [US/US]; 3027 Townsgate Road, #300, Westlake Village, CA 91361 (US).

(72) Inventor: **OSBORNE, David, W.**; 4215 Creekside Court, Fort Collins, CO 80525 (US).

(74) Agent: **POSTAL, Brett, A.**; Rothwell, Figg, Ernst & Manbeck, P.C., 607 14th Street Nw, Suite 800, Washington, DC 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

(54) Title: TOPICAL FORMULATION CONTAINING JAK INHIBITOR AND LAURETH-4




FIGURE 1

(57) Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.

[Continued on next page]

WO 2022/027041 A1

Published:
— *with international search report (Art. 21(3))*